| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 14, 2026 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/27/2026 | $45.00 | Buy | H.C. Wainwright |
| 4/10/2026 | $36.00 | Buy | Craig Hallum |
| 1/9/2026 | Buy | Roth Capital | |
| 10/6/2025 | $27.00 | Buy | Stifel |
| 10/6/2025 | $78.00 | Overweight | Piper Sandler |
| 10/6/2025 | $34.00 | Outperform | Leerink Partners |
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
SCHEDULE 13G/A - LB PHARMACEUTICALS INC (0001691082) (Subject)
424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
10-Q - LB PHARMACEUTICALS INC (0001691082) (Filer)
H.C. Wainwright initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $45.00
Craig Hallum initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $36.00
Roth Capital initiated coverage of LB Pharmaceuticals with a rating of Buy
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced that members of its executive team, will present and participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 Time: 2:35 p.m. ET H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference Date: Tuesday, June 16, 2026 Time: Presentation available on the LB Pharmaceuticals w
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1 trial of LB-102 in schizophrenia in The Journal of the American Medical Association (JAMA) Psychiatry Expanded pipeline following $100 million private placement with plans to initiate a Phase 2 trial of LB-102 in adjunctive treatment of major depressive disorder (MDD) in early 2027 Cash, cash equivalents, and marketable securities of $365.6 million as of March 31, 2026 expected to fund operations into Q2 2029, through multiple clinical milestones NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -
Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the publication in the Journal of the American Medical Association (JAMA) Psychiatry of its manuscript titled "Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults with Acute Schizo
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1 trial of LB-102 in schizophrenia in The Journal of the American Medical Association (JAMA) Psychiatry Expanded pipeline following $100 million private placement with plans to initiate a Phase 2 trial of LB-102 in adjunctive treatment of major depressive disorder (MDD) in early 2027 Cash, cash equivalents, and marketable securities of $365.6 million as of March 31, 2026 expected to fund operations into Q2 2029, through multiple clinical milestones NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -
NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced the appointment of Robert Lenz, M.D., Ph.D. to its Board of Directors. "We are delighted to welcome Rob to our Board as his depth of expertise in neuroscience R&D brings significant value to LB Pharma at a time when we are advancing LB-102 into late-stage clinical development across multiple indications," said Heather Turner, Chief Executive Officer of LB Pharmaceuticals
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactions and compliance. "We are delighted to welcome Minako to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Dr. Pazdera has broad expertise encompassing both financial and strateg